|Articles|May 1, 2006
- Volume 0 0
Venofer (iron sucrose injection, USP)
Advertisement
American Regent Inc(Shirley, NY) recentlyreceived FDA approval for2 new indications forVenofer. The product wasinitially approved for use in the treatmentof iron deficiency anemia inhemodialysis (HD) patients receivingan erythropoietin. Venofer now also isindicated for the treatment of irondeficiency anemia in peritoneal dialysis(PD) patients receiving an erythropoietinand in nondialysis chronic kidneydisease (CKD) patients receiving ornot receiving an erythropoietin. Theproduct can be administered via anintravenous push (100-mg [HD] and 200-mg [CKD] doses) or by infusion (300- and400-mg doses [PD]) depending on theindication. Venofer is available in 100-mg/5-mL single-dose vials. For moreinformation, visit www.venofer.com, orcall 800-645-1706.
Articles in this issue
almost 20 years ago
A Good Night's Rest—Helping the Patient with Insomniaalmost 20 years ago
Is Sleep-Driving for Real?almost 20 years ago
Painful Diabetic Neuropathy: Alternative Treatmentsalmost 20 years ago
A New Day Dawns for NCPA and NACDSalmost 20 years ago
compounding HOTLINEalmost 20 years ago
RESPy AWARDalmost 20 years ago
ULM STUDENT NEEDED TO HELPalmost 20 years ago
Must an Embezzling Pharmacist Repay Wages Received?almost 20 years ago
Web-based Program Aids Health Care Industryalmost 20 years ago
Depression: Identifying Symptoms and Appropriate TreatmentNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5